Adagene Inc. (ADAG)
2.06
0.11 (5.64%)
At close: Feb 20, 2025, 3:58 PM
2.04
-0.97%
After-hours: Feb 20, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 1.99 |
| Market Cap | 91.20M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -2.82 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 2.1 |
| Volume | 26,089 |
| Avg. Volume (20D) | 90,483 |
| Open | 1.95 |
| Previous Close | 1.95 |
| Day's Range | 2.03 - 2.08 |
| 52-Week Range | 1.64 - 3.65 |
| Beta | undefined |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 174
Stock Exchange NASDAQ
Ticker Symbol ADAG
Website https://www.adagene.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADAG stock is "Strong Buy." The 12-month stock price forecast is $8, which is an increase of 288.35% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago
+8.86%
Adagene shares are trading higher after the compan...
Unlock content with
Pro Subscription
